Last reviewed · How we verify
Placebo then Pioglitazone
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.
Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Placebo then Pioglitazone |
|---|---|
| Also known as | Actos, Glustin, Zactos |
| Sponsor | Medical University of South Carolina |
| Drug class | Thiazolidinedione |
| Target | PPAR-γ (Peroxisome proliferator-activated receptor gamma) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Pioglitazone is a thiazolidinedione that binds to PPAR-γ, a nuclear receptor involved in glucose and lipid metabolism. By activating PPAR-γ, it increases insulin sensitivity in muscle and adipose tissue, reduces hepatic glucose production, and improves glycemic control. This mechanism makes it effective for managing type 2 diabetes, particularly in insulin-resistant patients.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Weight gain
- Fluid retention / edema
- Hypoglycemia (when combined with other agents)
- Headache
- Upper respiratory tract infection
Key clinical trials
- Quantifying Hepatic Mitochondrial Fluxes in Humans (PHASE4)
- SGLT2i, Pioglitazone, and Ketone Production in T1D (PHASE3)
- Bioenergetic Effect of Pioglitazone in CLD-PH (PHASE2)
- Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin (NA)
- Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients (PHASE4)
- Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) (PHASE1, PHASE2)
- Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose (PHASE2)
- Cortisol Regulation in Polycystic Ovary Syndrome (PCOS) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo then Pioglitazone CI brief — competitive landscape report
- Placebo then Pioglitazone updates RSS · CI watch RSS
- Medical University of South Carolina portfolio CI